A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory

Trial Profile

A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 May 2017

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Dec 2016 Status changed from recruiting to discontinued.
    • 12 Jan 2016 Planned End Date changed from 1 Jan 2030 to 1 Nov 2020, as reported by ClinicalTrials.gov record.
    • 12 Jan 2016 Planned primary completion date changed from 1 Jan 2030 to 1 Nov 2020, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top